ALTAltimmune, Inc.

$331M

Q4 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M+150.9% YoY

Gross Profit

-$2M-58.8% margin

Operating Income

-$13M-447.3% margin

Net Income

-$9M-314.4% margin

EPS (Diluted)

$-13.15

QoQ Revenue Growth

-38.8%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$306,367

Balance Sheet

Total Assets

$63M

Total Liabilities

$14M

Stockholders' Equity

$49M

Cash & Equivalents

$9M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$1M	+150.9%
Gross Profit	-$2M	-$1M	-31.3%
Operating Income	-$13M	-$6M	-127.9%
Net Income	-$9M	$78M	-111.4%

ALT Q4 2017 Earnings — Altimmune, Inc. Revenue & Financial Results | Market Cap Arena